Optigo Biotherapeutics

Optigo Biotherapeutics is a private preclinical ophthalmology biotechnology company based in Vancouver, British Columbia, developing long-acting intravitreal biologics for retinal disease. The company’s core technology, the Vitreous Anchor Platform, uses proprietary protein domains that bind components of the vitreous gel to extend the half-life and durability of injected retinal biologics. Its lead efforts focus on anti-VEGF-based bifunctional biologics intended to reduce injection frequency for neovascular retinal diseases, with company materials indicating a goal of once- or twice-yearly dosing and eventually once-yearly therapy. Optigo also positions the platform for lifecycle extension of existing and future ophthalmic drugs, including potential use in geographic atrophy. The company appears to be actively seeking development partnerships in ophthalmology while advancing toward IND-enabling studies.